Michael Makris Shares 2 Fascinating Lessons from Hemophilia Care in Japan
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on LinkedIn:
”Two surprising facts I learnt about hemophilia care from my visit to Japan:
1. There are 7,000 patients with hemophilia A or B in Japan. They receive their care from 800 medical facilities. There are around 100 hemophilia treatment centres, but not all patients are seen here. Many patients have their hemophilia care provided by their local General Practitioners.
I find it difficult to understand how modern hemophilia care can be adequately provided outside hemophilia centres.
2. A number of consultant hematologists in Japan actually have hemophilia themselves. At dinner one evening I was sitting at a table with five consultant hematologists with hemophilia.”
During a recent visit to Japan, Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, observed two surprising aspects of hemophilia care in the country.
Firstly, among Japan’s 7,000 patients with hemophilia A or B, care is delivered across 800 medical facilities, with only around 100 designated hemophilia treatment centers.
Remarkably, many patients are managed by local General Practitioners rather than specialized centers—a model that raises questions about maintaining comprehensive, modern standards of care.
Secondly, Professor Michael Makris encountered a uniquely personal dimension of the medical community: several consultant hematologists in Japan live with hemophilia themselves.
In one memorable instance, he shared a dinner table with five consultant hematologists who have hemophilia—a testament to resilience and dedication within the field.
These reflections highlight distinctive features of Japan’s approach to hemophilia care, prompting consideration of care models and patient-professional dynamics worldwide.
More interesting facts about hemophilia featured in Hemostasis Today.
-
Oct 23, 2025, 06:03Melanie Daniel: Wonderful Presentation on Emicizumab by Mickael Rosa at ECTH
-
Oct 22, 2025, 06:17We Will Continue to Raise Awareness and Remind Rveryone That Donating Blood Means Saving Lives - Yeolyan Hematology and Oncology Center
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 24, 2025, 10:56Fabiano Cavalcante on Stenting of Stroke Patients with Tandem Carotid Lesions
-
Oct 23, 2025, 06:48Omid Seidizadeh Shares Deep Molecular Modeling and Mechanistic Insights into Type 2A VWD
-
Oct 23, 2025, 06:45Mélanie Roussel on D-Dimer Thresholds for Diagnosis of Pulmonary Embolism
-
Oct 23, 2025, 06:28Ramya Ramakrishnan on IDA Association with Depression
-
Oct 23, 2025, 06:07Cedric Hermans: Von Willebrand Disease Diagnosis - From Complexity to Simplicity
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 24, 2025, 10:48Melanie Daniel Congratulates Mickael Rosa and Antoine Rauch on Winning Bernd R. Binder Prize
-
Oct 24, 2025, 10:47Nan van Geloven Was Awarded The Prestigious Vidi Grant
-
Oct 23, 2025, 06:52Louise Bannon: Thrilled to Witness The Incredible Reach of This Year's World Thrombosis Day!
-
Oct 23, 2025, 06:50Caitlin Raymond to Speak at The 11th Annual Bloodless Medicine and Surgery Society Conference
-
Oct 22, 2025, 10:46Conversation with Ferran Nadeu – Touch Haematology Future Leader 2025